Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Leukemia

  Free Subscription


Articles published in Leuk Lymphoma

Retrieve available abstracts of 260 articles:
HTML format
Text format



Single Articles


    December 2018
  1. AUTORE F, Chiusolo P, Sora F, Giammarco S, et al
    Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid.
    Leuk Lymphoma. 2018 Dec 11:1-3. doi: 10.1080/10428194.2018.1522436.
    PubMed     Text format    


  2. LABRADOR J, Luno E, Vellenga E, Brunet S, et al
    Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy.
    Leuk Lymphoma. 2018 Dec 11:1-10. doi: 10.1080/10428194.2018.1522438.
    PubMed     Text format     Abstract available


  3. YAMAMOTO K, Yakushijin K, Ichikawa H, Okamura A, et al
    Coexpression of ETV6/MDS1/EVI1 and ETV6/EVI1 fusion transcripts in acute myeloid leukemia with t(3;12)(q26.2;p13) and thrombocytosis.
    Leuk Lymphoma. 2018 Dec 11:1-5. doi: 10.1080/10428194.2018.1529311.
    PubMed     Text format    


  4. MOLICA S, Giannarelli D, Mirabelli R, Levato L, et al
    The magnitude of improvement in progression-free survival with targeted therapy in relapsed/refractory chronic lymphocytic leukemia based on prognostic risk category: a systematic review and meta-analysis.
    Leuk Lymphoma. 2018 Dec 5:1-6. doi: 10.1080/10428194.2018.1543882.
    PubMed     Text format     Abstract available


  5. KIM S, Freeland-Graves JH, Babaei M, Sachdev PK, et al
    Quantifying the association between acute leukemia and serum zinc, copper, and selenium: a meta-analysis.
    Leuk Lymphoma. 2018 Dec 5:1-9. doi: 10.1080/10428194.2018.1540043.
    PubMed     Text format     Abstract available


  6. JIANG X, Cheng Y, Hu C, Zhang A, et al
    MicroRNA-221 sensitizes chronic myeloid leukemia cells to imatinib by targeting STAT5.
    Leuk Lymphoma. 2018 Dec 5:1-12. doi: 10.1080/10428194.2018.1543875.
    PubMed     Text format     Abstract available


  7. OCK CY, Seo H, Kim DY, Min BJ, et al
    Discovery of donor genotype associated with long-term survival of patients with hematopoietic stem cell transplantation in refractory acute myeloid leukemia.
    Leuk Lymphoma. 2018 Dec 3:1-7. doi: 10.1080/10428194.2018.1542142.
    PubMed     Text format     Abstract available


  8. MICHAILOV Y, Lunenfeld E, Kapelushnik J, Huleihel M, et al
    Leukemia and male infertility: past, present, and future.
    Leuk Lymphoma. 2018 Dec 3:1-10. doi: 10.1080/10428194.2018.1533126.
    PubMed     Text format     Abstract available


    November 2018
  9. NAMN Y, Furman RR, Crawford C
    A rare colonic manifestation of chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Nov 29:1-4. doi: 10.1080/10428194.2018.1459612.
    PubMed     Text format    


  10. SUN Y, Murty VV, Leeman-Neill R, Soderquist C, et al
    Cytogenetic analysis of adult T-Cell leukemia/lymphoma: evaluation of a Caribbean cohort.
    Leuk Lymphoma. 2018 Nov 27:1-3. doi: 10.1080/10428194.2018.1538506.
    PubMed     Text format    


  11. HARADA K, Yanada M, Machida S, Kanamori H, et al
    Prognostic impact of melphalan dose and total body irradiation use in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation with reduced-intensity conditioning.
    Leuk Lymphoma. 2018 Nov 20:1-10. doi: 10.1080/10428194.2018.1535115.
    PubMed     Text format     Abstract available


  12. DIAMANTOPOULOS PT, Kotsianidis I, Symeonidis A, Pappa V, et al
    Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system.
    Leuk Lymphoma. 2018 Nov 14:1-10. doi: 10.1080/10428194.2018.1540783.
    PubMed     Text format     Abstract available


  13. SOUMERAI JD, Ni A, Xing G, Huang J, et al
    Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials.
    Leuk Lymphoma. 2018 Nov 8:1-9. doi: 10.1080/10428194.2018.1540782.
    PubMed     Text format     Abstract available


  14. GURU MURTHY GS, Pondaiah SK, Abedin S, Atallah E, et al
    Incidence and survival of T-cell acute lymphoblastic leukemia in the United States.
    Leuk Lymphoma. 2018 Nov 8:1-8. doi: 10.1080/10428194.2018.1522442.
    PubMed     Text format     Abstract available


  15. NABHAN C, Kamat S, Karl Kish J
    Acute myeloid leukemia in the elderly: what constitutes treatment value?
    Leuk Lymphoma. 2018 Nov 8:1-7. doi: 10.1080/10428194.2018.1520992.
    PubMed     Text format     Abstract available


  16. RODRIGUEZ CM, Bussi C, Arroyo DS, Sastre D, et al
    Effects of rapamycin in combination with fludarabine on primary chronic lymphocytic leukemia cells.
    Leuk Lymphoma. 2018 Nov 8:1-5. doi: 10.1080/10428194.2018.1529309.
    PubMed     Text format    


  17. TAO S, Wang C, Chen Y, Deng Y, et al
    Long-term effect of all-trans retinoic acid and arsenic trioxide sequential maintenance in patients with acute promyelocytic leukemia.
    Leuk Lymphoma. 2018 Nov 8:1-9. doi: 10.1080/10428194.2018.1504941.
    PubMed     Text format     Abstract available


  18. ZAJAC-SPYCHALA O, Wachowiak J, Szmydki-Baran A, Hutnik L, et al
    Infectious complications in children treated for hodgkin and non-hodgkin lymphomas in polish pediatric leukemia/lymphoma study group: incidence, epidemiology and etiology.
    Leuk Lymphoma. 2018 Nov 5:1-9. doi: 10.1080/10428194.2018.1466293.
    PubMed     Text format     Abstract available


    October 2018
  19. POPP HD, Flach J, Brendel S, Ruppenthal S, et al
    Accumulation of DNA damage and alteration of the DNA damage response in monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Oct 31:1-10. doi: 10.1080/10428194.2018.1498494.
    PubMed     Text format     Abstract available


  20. ZHANG S, Zhou W, Li Y, Yu S, et al
    Co-expression of AML1-ETO and PML-RARa following treatment of de novo acute myeloid leukemia with AML1-ETO.
    Leuk Lymphoma. 2018 Oct 17:1-4. doi: 10.1080/10428194.2018.1520991.
    PubMed     Text format    


  21. CHEN J, Ngo D, Aldoss I, Shayani S, et al
    Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2018 Oct 15:1-6. doi: 10.1080/10428194.2018.1519811.
    PubMed     Text format     Abstract available


  22. BHANGOO MS, Saven A
    Secondary malignancies after treatment with single-agent vemurafenib in two patients with refractory hairy cell leukemia.
    Leuk Lymphoma. 2018 Oct 15:1-3. doi: 10.1080/10428194.2018.1519809.
    PubMed     Text format    


  23. SOBAS M, Montesinos P, Boluda B, Bernal T, et al
    An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens.
    Leuk Lymphoma. 2018 Oct 15:1-6. doi: 10.1080/10428194.2018.1516875.
    PubMed     Text format     Abstract available


  24. DAVIDS MS, Kim HT, Yu L, De Maeyer G, et al
    Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cytoreduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Oct 15:1-4. doi: 10.1080/10428194.2018.1519814.
    PubMed     Text format     Abstract available


  25. MEI C, Ren Y, Zhou X, Ye L, et al
    Clinical and biological characteristics of acute myeloid leukemia with 20-29% blasts: a retrospective single-center study.
    Leuk Lymphoma. 2018 Oct 10:1-10. doi: 10.1080/10428194.2018.1515938.
    PubMed     Text format     Abstract available


  26. MOLICA S, Giannarelli D, Levato L, Mirabelli R, et al
    A simple score based on geriatric assessment predicts survival in elderly newly diagnosed chronic lymphocytic leukemia patients.
    Leuk Lymphoma. 2018 Oct 2:1-3. doi: 10.1080/10428194.2018.1508674.
    PubMed     Text format    


  27. NIEBOROWSKA-SKORSKA M, Maifrede S, Ye M, Toma M, et al
    Non-NAD-like PARP1 inhibitor enhanced synthetic lethal effect of NAD-like PARP inhibitors against BRCA1-deficient leukemia.
    Leuk Lymphoma. 2018 Oct 2:1-4. doi: 10.1080/10428194.2018.1520988.
    PubMed     Text format    


  28. CHEN X, Wang F, Zhang Y, Wang M, et al
    Panoramic view of common fusion genes in a large cohort of Chinese de novo acute myeloid leukemia patients.
    Leuk Lymphoma. 2018 Oct 2:1-8. doi: 10.1080/10428194.2018.1516876.
    PubMed     Text format     Abstract available


  29. BUCKLEY SA, Percival ME, Othus M, Halpern AB, et al
    A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study.
    Leuk Lymphoma. 2018 Oct 2:1-7. doi: 10.1080/10428194.2018.1516036.
    PubMed     Text format     Abstract available


  30. MILLER KC, Al-Kali A, Shah MV, Hogan WJ, et al
    Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients.
    Leuk Lymphoma. 2018 Oct 2:1-10. doi: 10.1080/10428194.2018.1509318.
    PubMed     Text format     Abstract available


  31. WESTHUS J, Noppeney R, Duhrsen U, Hanoun M, et al
    FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemia.
    Leuk Lymphoma. 2018 Oct 2:1-9. doi: 10.1080/10428194.2018.1508670.
    PubMed     Text format     Abstract available


  32. BARRIENTOS JC, Burger JA, Byrd JC, Hillmen P, et al
    Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib.
    Leuk Lymphoma. 2018 Oct 2:1-6. doi: 10.1080/10428194.2018.1512710.
    PubMed     Text format     Abstract available


  33. SHETH V, Nachmias B, Grisariu S, Avni B, et al
    Augmented myeloablative conditioning with thiotepa in acute myeloid leukemia - improved outcomes with similar toxicity.
    Leuk Lymphoma. 2018 Oct 2:1-8. doi: 10.1080/10428194.2018.1510495.
    PubMed     Text format     Abstract available


  34. CHEN CI, Paul H, Snitzler S, Kakar S, et al
    A phase 2 study of lenalidomide and dexamethasone in previously untreated patients with chronic lymphocytic leukemia (CLL).
    Leuk Lymphoma. 2018 Oct 2:1-10. doi: 10.1080/10428194.2018.1508669.
    PubMed     Text format     Abstract available


  35. ROSSOFF J, Akpan I, Platanias LC
    Spontaneous remission in congenital leukemia.
    Leuk Lymphoma. 2018;59:2271-2272.
    PubMed     Text format    


    September 2018
  36. D'ARENA G, Seneca E, Migliaccio I, De Feo V, et al
    Oxidative stress in chronic lymphocytic leukemia: still a matter of debate.
    Leuk Lymphoma. 2018 Sep 20:1-9. doi: 10.1080/10428194.2018.1509317.
    PubMed     Text format     Abstract available


  37. MCMAHON CM, Perl AE
    Management of primary refractory acute myeloid leukemia in the era of targeted therapies.
    Leuk Lymphoma. 2018 Sep 20:1-14. doi: 10.1080/10428194.2018.1504937.
    PubMed     Text format     Abstract available


  38. EREN R, Karismaz A, Karatas D, Dogu MH, et al
    Comparison of clinical features and survival between young and old chronic lymphocytic leukemia patients: a single center study from Turkey.
    Leuk Lymphoma. 2018 Sep 6:1-6. doi: 10.1080/10428194.2018.1509316.
    PubMed     Text format     Abstract available


  39. SAENZ-DE-VITERI M, Cudrnak T
    Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated with ibrutinib.
    Leuk Lymphoma. 2018 Sep 6:1-3. doi: 10.1080/10428194.2018.1508673.
    PubMed     Text format    


  40. FERREIRA LAM, Capannacci J, Hokama NK, Nogueira CR, et al
    Circulating microRNAs expression profile in newly diagnosed and imatinib treated chronic phase - chronic myeloid leukemia.
    Leuk Lymphoma. 2018 Sep 6:1-7. doi: 10.1080/10428194.2018.1499905.
    PubMed     Text format     Abstract available


  41. GIANFELICI V, Messina M, Paoloni F, Peragine N, et al
    IL7R overexpression in adult acute lymphoblastic leukemia is associated to JAK/STAT pathway mutations and identifies patients who could benefit from targeted therapies.
    Leuk Lymphoma. 2018 Sep 6:1-4. doi: 10.1080/10428194.2018.1499906.
    PubMed     Text format    


  42. KNEZ V, Liu X, Schowinsky J, Pan Z, et al
    Clinicopathologic and genetic spectrum of infantile B-lymphoblastic leukemia: a multi-institutional study.
    Leuk Lymphoma. 2018 Sep 6:1-8. doi: 10.1080/10428194.2018.1508667.
    PubMed     Text format     Abstract available


  43. HE C, Luo B, Jiang N, Liang Y, et al
    OncomiR or antioncomiR: Role of miRNAs in Acute Myeloid Leukemia.
    Leuk Lymphoma. 2018 Sep 6:1-12. doi: 10.1080/10428194.2018.1480769.
    PubMed     Text format     Abstract available


  44. KUTTIKRISHNAN S, Siveen KS, Prabhu KS, Khan AQ, et al
    Sanguinarine suppresses growth and induces apoptosis in childhood acute lymphoblastic leukemia.
    Leuk Lymphoma. 2018 Sep 6:1-13. doi: 10.1080/10428194.2018.1494270.
    PubMed     Text format     Abstract available


    August 2018
  45. BORLENGHI E, Cattaneo C, Schieppati F, Gramegna D, et al
    Acute promyelocytic leukemia in patients aged >70 years is not rare and highly curable: a single center series of 21 unselected patients.
    Leuk Lymphoma. 2018 Aug 30:1-4. doi: 10.1080/10428194.2018.1492126.
    PubMed     Text format    


  46. CAO M, Carrasco RD, Dubuc AM, Dal Cin P, et al
    ZMYM2-FGFR1 fusion as secondary change in acute myeloid leukemia.
    Leuk Lymphoma. 2018 Aug 30:1-3. doi: 10.1080/10428194.2018.1493733.
    PubMed     Text format    


  47. SPEZIALI C, Daly A, Abuhaleeqa M, Nitta J, et al
    Fludarabine, busulfan, and low-dose TBI conditioning versus cyclophosphamide and TBI in allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia.
    Leuk Lymphoma. 2018 Aug 30:1-10. doi: 10.1080/10428194.2018.1493734.
    PubMed     Text format     Abstract available


  48. JABBOUR EJ, Siegartel LR, Lin J, Lingohr-Smith M, et al
    Impact of earlier versus later monitoring on disease progression and healthcare costs among patients with chronic myeloid leukemia in the United States.
    Leuk Lymphoma. 2018 Aug 20:1-7. doi: 10.1080/10428194.2018.1492124.
    PubMed     Text format     Abstract available


  49. NATARAJAN H, Kumar L, Bakhshi S, Sharma A, et al
    Imatinib trough levels: a potential biomarker to predict cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia.
    Leuk Lymphoma. 2018 Aug 20:1-8. doi: 10.1080/10428194.2018.1485907.
    PubMed     Text format     Abstract available


  50. OLSHANSKAYA Y, Kazakova A, Tsaur G, Zerkalenkova E, et al
    Clinical significance of cytogenetic changes in childhood T-cell acute lymphoblastic leukemia: results of the multicenter group Moscow-Berlin (MB).
    Leuk Lymphoma. 2018 Aug 1:1-7. doi: 10.1080/10428194.2018.1485904.
    PubMed     Text format     Abstract available


    July 2018
  51. XU YP, Wieten L, Wang SX, Cai Y, et al
    Clinical significance of HLA-E genotype and surface/soluble expression levels between healthy individuals and patients with acute leukemia.
    Leuk Lymphoma. 2018 Jul 3:1-8. doi: 10.1080/10428194.2018.1474521.
    PubMed     Text format     Abstract available


  52. CHELLAPANDIAN D, Pole JD, Nathan PC, Sung L, et al
    Congestive heart failure among children with acute leukemia: a population-based matched cohort study.
    Leuk Lymphoma. 2018 Jul 3:1-10. doi: 10.1080/10428194.2018.1474522.
    PubMed     Text format     Abstract available


  53. KAIFIE A, Schikowsky C, Vasko T, Kraus T, et al
    Additional benefits of telomere length (TL) measurements in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Jul 3:1-3. doi: 10.1080/10428194.2018.1482544.
    PubMed     Text format    


  54. KATHIRAVAN M, Singh M, Bhatia P, Trehan A, et al
    Deletion of CDKN2A/B is associated with inferior relapse free survival in pediatric B cell acute lymphoblastic leukemia.
    Leuk Lymphoma. 2018 Jul 3:1-9. doi: 10.1080/10428194.2018.1482542.
    PubMed     Text format     Abstract available


  55. JURCZYSZYN A, Castillo JJ, Avivi I, Czepiel J, et al
    Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients.
    Leuk Lymphoma. 2018 Jul 2:1-6. doi: 10.1080/10428194.2018.1473574.
    PubMed     Text format     Abstract available


  56. ERBILGIN Y, Eskazan AE, Hatirnaz Ng O, Salihoglu A, et al
    Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors.
    Leuk Lymphoma. 2018 Jul 2:1-9. doi: 10.1080/10428194.2018.1473573.
    PubMed     Text format     Abstract available


  57. STAHL M, DeVeaux M, Montesinos P, Itzykson R, et al
    Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia.
    Leuk Lymphoma. 2018 Jul 2:1-4. doi: 10.1080/10428194.2018.1468893.
    PubMed     Text format    


  58. LOZANO C, Brun S, Arnaud A, Gaulard P, et al
    Complete remission of agranulocytosis after splenectomy in a variant form of T-cell large granular lymphocyte leukemia.
    Leuk Lymphoma. 2018 Jul 2:1-4. doi: 10.1080/10428194.2018.1471601.
    PubMed     Text format    


    June 2018
  59. CAPRIA S, Pepe S, Trisolini SM, Testi AM, et al
    Autologous stem cell transplant in acute lymphoblastic leukemia: prognostic impact of pre-transplant minimal residual disease.
    Leuk Lymphoma. 2018 Jun 26:1-3. doi: 10.1080/10428194.2018.1468895.
    PubMed     Text format    


  60. PODSZYWALOW-BARTNICKA P, Maifrede S, Le BV, Nieborowska-Skorska M, et al
    PARP1 inhibitor eliminated imatinib-refractory chronic myeloid leukemia cells in bone marrow microenvironment conditions.
    Leuk Lymphoma. 2018 Jun 22:1-3. doi: 10.1080/10428194.2018.1471602.
    PubMed     Text format    


  61. CHEN CI, Paul H, Le LW, Wei EN, et al
    A phase 2 study of ofatumumab (Arzerra((R))) in combination with a pan-AKT inhibitor (afuresertib) in previously treated patients with chronic lymphocytic leukemia (CLL).
    Leuk Lymphoma. 2018 Jun 19:1-9. doi: 10.1080/10428194.2018.1468892.
    PubMed     Text format     Abstract available


  62. THAN H, Lye WK, Sng C, Allen JC Jr, et al
    BIM deletion polymorphism profiling complements prognostic values of risk scores in imatinib-treated Asian chronic myeloid leukemia patients.
    Leuk Lymphoma. 2018 Jun 19:1-4. doi: 10.1080/10428194.2018.1461863.
    PubMed     Text format    


  63. CRASSINI K, Pyke T, Shen Y, Stevenson WS, et al
    Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cells.
    Leuk Lymphoma. 2018 Jun 18:1-12. doi: 10.1080/10428194.2018.1455974.
    PubMed     Text format     Abstract available


  64. STRATI P, Gabutti C, Thompson PA, Kontoyiannis DP, et al
    Cytomegalovirus reactivation can be a cause of DAT-negative hemolytic anemia in patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Jun 18:1-3. doi: 10.1080/10428194.2018.1474527.
    PubMed     Text format    


  65. PAPAGEORGIOU SG, Diamantopoulos MA, Kontos CK, Bouchla A, et al
    MicroRNA-92a-3p overexpression in peripheral blood mononuclear cells is an independent predictor of prolonged overall survival of patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Jun 18:1-10. doi: 10.1080/10428194.2018.1461861.
    PubMed     Text format     Abstract available


  66. YAMAMOTO K, Yakushijin K, Ichikawa H, Kakiuchi S, et al
    Expression of a novel ZMYND11/MBTD1 fusion transcript in CD7(+)CD56(+) acute myeloid leukemia with t(10;17)(p15;q21).
    Leuk Lymphoma. 2018 Jun 18:1-5. doi: 10.1080/10428194.2018.1464157.
    PubMed     Text format    


  67. BERTOLI S, Tavitian S, Berard E, Gadaud N, et al
    Outcome of relapsed or refractory acute myeloid leukemia treated with intensive salvage chemotherapy in real life in comparison to intermediate dose cytarabine in phase 3 studies.
    Leuk Lymphoma. 2018 Jun 12:1-4. doi: 10.1080/10428194.2018.1464156.
    PubMed     Text format    


    May 2018
  68. PLEYER C, Wiestner A, Sun C
    Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 May 15:1-9. doi: 10.1080/10428194.2018.1457147.
    PubMed     Text format     Abstract available


  69. YOGARAJAH M, Montgomery N, Matson M, Blanchard L, et al
    Clonal evolution of Philadelphia chromosome in acute myeloid leukemia after azacitidine treatment.
    Leuk Lymphoma. 2018 May 11:1-3. doi: 10.1080/10428194.2018.1459614.
    PubMed     Text format    


  70. OHANIAN M, Rozovski U, Kanagal-Shamanna R, Abruzzo LV, et al
    MYC protein expression is an important prognostic factor in acute myeloid leukemia.
    Leuk Lymphoma. 2018 May 9:1-12. doi: 10.1080/10428194.2018.1464158.
    PubMed     Text format     Abstract available


  71. KRULL K, Kunstreich M, Bronsema A, Bleckmann K, et al
    Osteonecrosis in children with acute lymphoblastic leukemia at initial diagnosis and prior to any chemotherapy.
    Leuk Lymphoma. 2018 May 2:1-7. doi: 10.1080/10428194.2018.1466292.
    PubMed     Text format     Abstract available


  72. LICATA MJ, Janakiram M, Tan S, Fang Y, et al
    Diagnostic challenges of adult T-cell leukemia/lymphoma in North America - a clinical, histological, and immunophenotypic correlation with a workflow proposal.
    Leuk Lymphoma. 2018;59:1188-1194.
    PubMed     Text format     Abstract available


    April 2018
  73. STAHL M, Pine A, Hendrickson JE, Litzow MR, et al
    Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey().
    Leuk Lymphoma. 2018 Apr 18:1-4. doi: 10.1080/10428194.2018.1452219.
    PubMed     Text format    


  74. TAKEI T, Yokoyama K, Shimizu E, Konuma T, et al
    Azacitidine effectively reduces TP53-mutant leukemic cell burden in secondary acute myeloid leukemia after cord blood transplantation.
    Leuk Lymphoma. 2018 Apr 12:1-2. doi: 10.1080/10428194.2018.1443335.
    PubMed     Text format    


  75. REDNER RL, Beumer JH, Kropf P, Agha M, et al
    A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia.
    Leuk Lymphoma. 2018 Apr 4:1-7. doi: 10.1080/10428194.2018.1443330.
    PubMed     Text format     Abstract available


  76. OJAMIES PN, Kontro M, Edgren H, Ellonen P, et al
    Case studies investigating genetic heterogeneity between anatomically distinct bone marrow compartments in acute myeloid leukemia.
    Leuk Lymphoma. 2018 Apr 4:1-4. doi: 10.1080/10428194.2018.1453067.
    PubMed     Text format    


  77. ZHANG H, Liang Z, Hu Y, Wang X, et al
    The effectiveness of interferon-alpha combined with imatinib in patient with chronic myeloid leukemia harboring T315I BCR-ABL1 mutation.
    Leuk Lymphoma. 2018 Apr 4:1-2. doi: 10.1080/10428194.2018.1443329.
    PubMed     Text format    


  78. VAN DER STRATEN L, Dinmohamed AG, Westerweel PE, Langerak AW, et al
    Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy.
    Leuk Lymphoma. 2018 Apr 4:1-5. doi: 10.1080/10428194.2018.1452215.
    PubMed     Text format    


  79. IMAGAWA J
    Switching from all-trans retinoic acid to arsenic trioxide for newly diagnosed acute promyelocytic leukemia.
    Leuk Lymphoma. 2018 Apr 4:1-3. doi: 10.1080/10428194.2018.1443333.
    PubMed     Text format    


  80. KUROSAWA S, Toya T, Kishida Y, Nagata A, et al
    Outcome of patients with acute undifferentiated leukemia after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2018 Apr 4:1-4. doi: 10.1080/10428194.2018.1441410.
    PubMed     Text format    


  81. HUANG J, Hong M, Zhu Y, Zhao H, et al
    Decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin is as effective as standard dose chemotherapy in the induction treatment for patients aged from 55 to 69 years old with newly diagnosed acute myeloid leukemia.
    Leuk Lymphoma. 2018 Apr 4:1-10. doi: 10.1080/10428194.2018.1443328.
    PubMed     Text format     Abstract available


    March 2018
  82. HOVERSTEN K, Vallapureddy R, Lasho T, Finke C, et al
    Nonhepatosplenic extramedullary manifestations of chronic myelomonocytic leukemia: clinical, molecular and prognostic correlates.
    Leuk Lymphoma. 2018 Mar 27:1-4. doi: 10.1080/10428194.2018.1452212.
    PubMed     Text format    


  83. MACDONALD RJ, Bunaciu RP, Ip V, Dai D, et al
    Src family kinase inhibitor bosutinib enhances retinoic acid-induced differentiation of HL-60 leukemia cells.
    Leuk Lymphoma. 2018 Mar 23:1-11. doi: 10.1080/10428194.2018.1452213.
    PubMed     Text format     Abstract available


  84. SORIGUE M, Orna E, Sancho JM
    Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review.
    Leuk Lymphoma. 2018 Mar 21:1-10. doi: 10.1080/10428194.2018.1448085.
    PubMed     Text format     Abstract available


    February 2018
  85. JIANG JG, Xu Y, Wu Z, Ni H, et al
    Acute myeloid leukemia developed in Ph- cells with MLL gene amplification in a patient with chronic myelogenous leukemia.
    Leuk Lymphoma. 2018 Feb 23:1-3. doi: 10.1080/10428194.2018.1436174.
    PubMed     Text format    


  86. DE LUCA G, Trasarti S, Bizzoni L, Del Giudice I, et al
    Lymphomatoid granulomatosis and large granular lymphocyte leukemia, a rare association of two lymphoproliferative disorders.
    Leuk Lymphoma. 2018 Feb 23:1-4. doi: 10.1080/10428194.2018.1439583.
    PubMed     Text format    


  87. CASEY N, Fujiwara H, Azuma T, Murakami Y, et al
    An unusual, CD4 and CD8 dual-positive, CD25 negative, tumor cell phenotype in a patient with adult T-cell leukemia/lymphoma.
    Leuk Lymphoma. 2018 Feb 21:1-3. doi: 10.1080/10428194.2018.1439168.
    PubMed     Text format    


  88. MOLICA S, Levato L, Mirabelli R, Tedeschi A, et al
    Feasibility and safety of therapy with ibrutinib after antiviral control of hepatitis B virus (HBV) reactivation in chronic lymphocytic leukemia patients.
    Leuk Lymphoma. 2018 Feb 21:1-3. doi: 10.1080/10428194.2018.1436175.
    PubMed     Text format    


  89. ROZOVSKI U, Harris DM, Li P, Liu Z, et al
    Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2018 Feb 21:1-6. doi: 10.1080/10428194.2018.1439167.
    PubMed     Text format     Abstract available


  90. VAN DE LOUW A, Desai RJ, Zhu J, Claxton DF, et al
    Characteristics of early acute respiratory distress syndrome in newly diagnosed acute myeloid leukemia.
    Leuk Lymphoma. 2018 Feb 12:1-8. doi: 10.1080/10428194.2018.1435874.
    PubMed     Text format     Abstract available


  91. IKAWA Y, Nishimura R, Maeba H, Fujiki T, et al
    Deep spontaneous molecular remission in a patient with congenital acute myeloid leukemia expressing a novel MOZ-p300 fusion transcript.
    Leuk Lymphoma. 2018 Feb 12:1-3. doi: 10.1080/10428194.2018.1434885.
    PubMed     Text format    


  92. KARANTANOU C, Godavarthy PS, Krause DS
    Targeting the bone marrow microenvironment in acute leukemia.
    Leuk Lymphoma. 2018 Feb 12:1-11. doi: 10.1080/10428194.2018.1434886.
    PubMed     Text format     Abstract available


  93. KRUPAR R, Schreiber C, Offermann A, Lengerke C, et al
    In silico analysis of anti-leukemia immune response and immune evasion in acute myeloid leukemia.
    Leuk Lymphoma. 2018 Feb 12:1-4. doi: 10.1080/10428194.2018.1434883.
    PubMed     Text format    


  94. SMIRNIKHINA SA, Chelysheva EY, Lavrov AV, Kochergin-Nikitsky KS, et al
    Genetic markers of stable molecular remission in chronic myeloid leukemia after targeted therapy discontinuation.
    Leuk Lymphoma. 2018 Feb 9:1-4. doi: 10.1080/10428194.2018.1434880.
    PubMed     Text format    


  95. ZAJAC-SPYCHALA O, Pawlak M, Karmelita-Katulska K, Pilarczyk J, et al
    Anti-leukemic treatment-induced neurotoxicity in long-term survivors of childhood acute lymphoblastic leukemia: impact of reduced central nervous system radiotherapy and intermediate- to high-dose methotrexate.
    Leuk Lymphoma. 2018 Feb 9:1-10. doi: 10.1080/10428194.2018.1434879.
    PubMed     Text format     Abstract available


  96. DERRIEUX C, Freynet N, Frayfer J, Delabesse E, et al
    A case of B-cell precursor acute lymphoblastic leukemia with IL3-IGH rearrangement revealed by thromboembolism and marked eosinophilia.
    Leuk Lymphoma. 2018 Feb 9:1-4. doi: 10.1080/10428194.2018.1430796.
    PubMed     Text format    


  97. ALVAREZ E, Muffly L, Li Q, Brunson A, et al
    Care at specialized cancer centers among young adults with acute lymphoblastic leukemia in California.
    Leuk Lymphoma. 2018 Feb 9:1-3. doi: 10.1080/10428194.2018.1427856.
    PubMed     Text format    


  98. HE F, Sapkota S, Parker S, Defor T, et al
    A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia.
    Leuk Lymphoma. 2018 Feb 7:1-8. doi: 10.1080/10428194.2018.1433297.
    PubMed     Text format     Abstract available


  99. FLOWERS CR, Nabhan C, Kay NE, Mato A, et al
    Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect((R)) CLL cohort study.
    Leuk Lymphoma. 2018 Feb 7:1-9. doi: 10.1080/10428194.2018.1427860.
    PubMed     Text format     Abstract available


  100. TORREBADELL M, Diaz-Beya M, Kalko SG, Pratcorona M, et al
    A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia.
    Leuk Lymphoma. 2018 Feb 2:1-11. doi: 10.1080/10428194.2017.1422859.
    PubMed     Text format     Abstract available


  101. IMBERT V, Nebout M, Mary D, Endou H, et al
    Co-targeting intracellular pH and essential amino acid uptake cooperates to induce cell death of T-ALL/LL cells.
    Leuk Lymphoma. 2018;59:460-468.
    PubMed     Text format     Abstract available


  102. THORP BC, Badoux X
    Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.
    Leuk Lymphoma. 2018;59:311-320.
    PubMed     Text format     Abstract available


    January 2018
  103. SCIUME M, Fracchiolla NS, Cortelezzi A
    Severe hypofibrinogenemia associated with imatinib and prednisone therapy in Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Leuk Lymphoma. 2018 Jan 31:1-2. doi: 10.1080/10428194.2018.1429603.
    PubMed     Text format    


  104. ZHANG Y, Qu S, Wang Q, Li J, et al
    A novel fusion of PDGFRB to TSC1, an intrinsic suppressor of mTOR-signaling pathway, in a chronic eosinophilic leukemia patient with t(5;9)(q32;q34).
    Leuk Lymphoma. 2018 Jan 31:1-3. doi: 10.1080/10428194.2018.1427855.
    PubMed     Text format    


  105. ANDO T, Kojima K, Sano H, Kidoguchi K, et al
    Successful treatment of post-transplant relapsed adult T cell leukemia after cord blood transplantation with low-dose, short-term lenalidomide.
    Leuk Lymphoma. 2018 Jan 31:1-4. doi: 10.1080/10428194.2018.1427859.
    PubMed     Text format    


  106. RICARD L, Abisror N, Droin N, Selimoglu-Buet D, et al
    Retroperitoneal fibrosis as extramedullary hematopoiesis of a chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2018 Jan 25:1-3. doi: 10.1080/10428194.2018.1427857.
    PubMed     Text format    


  107. PANDEY G, Bakhshi S, Thakur B, Jain P, et al
    Prognostic significance of cathepsin L expression in pediatric acute myeloid leukemia.
    Leuk Lymphoma. 2018 Jan 18:1-13. doi: 10.1080/10428194.2017.1422865.
    PubMed     Text format     Abstract available


  108. GUILLEM V, Calabuig M, Brunet S, Esteve J, et al
    Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival.
    Leuk Lymphoma. 2018 Jan 18:1-11. doi: 10.1080/10428194.2017.1422858.
    PubMed     Text format     Abstract available


  109. LENNMYR EB, Kozlowski P, Ahlberg L, Bernell P, et al
    Real-world data on first relapse of acute lymphoblastic leukemia in patients >55 years.
    Leuk Lymphoma. 2018 Jan 18:1-4. doi: 10.1080/10428194.2017.1416369.
    PubMed     Text format    


  110. BODDU P, Kantarjian H, Ravandi F, Garcia-Manero G, et al
    Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia.
    Leuk Lymphoma. 2018 Jan 17:1-4. doi: 10.1080/10428194.2017.1422864.
    PubMed     Text format    


  111. CUI J, Zhu Z, Liu S, Li Q, et al
    Monitoring of leukemia stem cells in chronic myeloid leukemia patients.
    Leuk Lymphoma. 2018 Jan 16:1-3. doi: 10.1080/10428194.2017.1421755.
    PubMed     Text format    


  112. YANG M, Xing S, Ou HL, Zhang L, et al
    Vibsanol A induces differentiation of acute myeloid leukemia cells via activation of the PKC signaling pathway and induction of ROS.
    Leuk Lymphoma. 2018 Jan 16:1-9. doi: 10.1080/10428194.2017.1421754.
    PubMed     Text format     Abstract available


  113. ZHOU H, Xu RZ, Gu Y, Shi PF, et al
    Targeting of phospho-eIF4E by homoharringtonine eradicates a distinct subset of human acute myeloid leukemia.
    Leuk Lymphoma. 2018 Jan 15:1-13. doi: 10.1080/10428194.2017.1390229.
    PubMed     Text format     Abstract available


  114. SHAO H, Zeng Z, Cen J, Zhang J, et al
    The impact of early molecular response in children and adolescents with chronic myeloid leukemia treated with imatinib: a single-center study from China.
    Leuk Lymphoma. 2018 Jan 15:1-7. doi: 10.1080/10428194.2017.1422860.
    PubMed     Text format     Abstract available


  115. COSIMATO V, Scalia G, Raia M, Gentile L, et al
    Surface endoglin (CD105) expression on acute leukemia blast cells: an extensive flow cytometry study of 1002 patients.
    Leuk Lymphoma. 2018 Jan 15:1-4. doi: 10.1080/10428194.2017.1416366.
    PubMed     Text format    


  116. HANNON M, Wilde L, Nwaoduah N, Kasner M, et al
    Chronic myelomonocytic leukemia with central nervous system involvement.
    Leuk Lymphoma. 2018 Jan 11:1-2. doi: 10.1080/10428194.2017.1422866.
    PubMed     Text format    


  117. CRAMER P, Fraser G, Santucci-Silva R, Grosicki S, et al
    Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in t
    Leuk Lymphoma. 2018 Jan 3:1-10. doi: 10.1080/10428194.2017.1416364.
    PubMed     Text format     Abstract available


  118. RUAN J, Gao S, Yang J, Li H, et al
    WT1 protein is cleaved by caspase-3 in apoptotic leukemic cells.
    Leuk Lymphoma. 2018;59:162-170.
    PubMed     Text format     Abstract available


  119. GUO BB, Liang J, Allcock RJN, Mirzai B, et al
    A mutation in PTPN11 may drive leukemic transformation in a case of essential thrombocythemia.
    Leuk Lymphoma. 2018;59:245-248.
    PubMed     Text format    


  120. JANAKIRAM M, Verma A, Wang Y, Budhathoki A, et al
    Accelerated leukemic transformation after haplo-identical transplantation for hydroxyurea-treated sickle cell disease.
    Leuk Lymphoma. 2018;59:241-244.
    PubMed     Text format    


  121. ZHANG Y, Cheng Z, Yan WZ, Liu SF, et al
    Molecular characterization and therapeutic reaction to dasatinib in a CML patient harboring a novel e8a2 BCR-ABL1 transcript with a somatic mutation in TP53BP2 and cadherin-10 genes.
    Leuk Lymphoma. 2018;59:233-236.
    PubMed     Text format    


    December 2017
  122. HANIF A, Wang ES, Thompson JE, Baron JI, et al
    Combining blinatumomab with targeted therapy for BCR-ABL mutant relapsed/refractory acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Dec 18:1-3. doi: 10.1080/10428194.2017.1411595.
    PubMed     Text format    


  123. YABUSHITA T, Satake H, Maruoka H, Morita M, et al
    Expression of multiple leukemic stem cell markers is associated with poor prognosis in de novo acute myeloid leukemia.
    Leuk Lymphoma. 2017 Dec 18:1-8. doi: 10.1080/10428194.2017.1410888.
    PubMed     Text format     Abstract available


  124. GAY ND, Kozin E, Okada C, Danilov AV, et al
    Obinutuzumab monotherapy in previously untreated chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Dec 18:1-3. doi: 10.1080/10428194.2017.1410890.
    PubMed     Text format    


  125. HALDER A, Nayak KB, Chakraborty S
    Ecotopic viral integration site 1 (EVI1) transcriptionally targets talin1 (TLN1) and upregulates its expression in chronic myeloid leukemia.
    Leuk Lymphoma. 2017 Dec 7:1-3. doi: 10.1080/10428194.2017.1406089.
    PubMed     Text format    


  126. LI H, Zhang W, Kuang P, Ye Y, et al
    Combination of IKZF1 deletion and early molecular response show significant roles on prognostic stratification in Philadelphia chromosome-positive acute lymphoblastic leukemia patients.
    Leuk Lymphoma. 2017 Dec 7:1-9. doi: 10.1080/10428194.2017.1406933.
    PubMed     Text format     Abstract available


  127. HERNANDEZ-GONZALEZ O, Ortiz-Zamudio JJ, Rodriguez-Pinal CJ, Alvarado-Morales I, et al
    Genetic polymorphisms of arylamine N-acetyltransferases 1 and 2 and the likelihood of developing pediatric acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Dec 7:1-8. doi: 10.1080/10428194.2017.1406090.
    PubMed     Text format     Abstract available


  128. LEI H, Wang W, Wu Y
    Targeting oncoproteins for degradation by small molecules in myeloid leukemia.
    Leuk Lymphoma. 2017 Dec 4:1-8. doi: 10.1080/10428194.2017.1403600.
    PubMed     Text format     Abstract available


  129. GUPTA SK, Bakhshi S, Chopra A, Kamal VK, et al
    Molecular genetic profile in BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia can further refine outcome prediction in addition to that by end-induction minimal residual disease detection.
    Leuk Lymphoma. 2017 Dec 3:1-6. doi: 10.1080/10428194.2017.1408087.
    PubMed     Text format     Abstract available


  130. CHENG WY, Zhu YM, Cheng S, Chen YS, et al
    Development of B-cell prolymphocytic leukemia in a patient with splenic diffuse red pulp small B-cell lymphoma.
    Leuk Lymphoma. 2017 Dec 3:1-4. doi: 10.1080/10428194.2017.1405397.
    PubMed     Text format    



  131. XVII International Workshop on Chronic Lymphocytic Leukemia 2017 May 12--15, 2017, New York.
    Leuk Lymphoma. 2017;58.
    PubMed     Text format    


    November 2017
  132. RUGGIU M, Oberkampf F, Ghez D, Cony-Makhoul P, et al
    Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia.
    Leuk Lymphoma. 2017 Nov 28:1-7. doi: 10.1080/10428194.2017.1397666.
    PubMed     Text format     Abstract available


  133. RIBERA JM, Morgades M, Montesinos P, Martino R, et al
    Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Nov 22:1-10. doi: 10.1080/10428194.2017.1397661.
    PubMed     Text format     Abstract available


  134. KANNA R, Choudhary G, Ramachandra N, Steidl U, et al
    STAT3 inhibition as a therapeutic strategy for leukemia.
    Leuk Lymphoma. 2017 Nov 22:1-7. doi: 10.1080/10428194.2017.1397668.
    PubMed     Text format     Abstract available


  135. PEI R, Si T, Lu Y, Zhou JX, et al
    Salvianolic acid A, a novel PI3K/Akt inhibitor, induces cell apoptosis and suppresses tumor growth in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Nov 22:1-9. doi: 10.1080/10428194.2017.1399314.
    PubMed     Text format     Abstract available


  136. GOHIL SH, Maciocia N, Patrick P, Roberts T, et al
    LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Nov 22:1-4. doi: 10.1080/10428194.2017.1399311.
    PubMed     Text format    


  137. PATNAIK MM
    The importance of FLT3 mutational analysis in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Nov 22:1-14. doi: 10.1080/10428194.2017.1399312.
    PubMed     Text format     Abstract available


  138. AYED AO, Parikh SA
    Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy.
    Leuk Lymphoma. 2017 Nov 8:1-10. doi: 10.1080/10428194.2017.1397665.
    PubMed     Text format     Abstract available


  139. MARTINEZ-TRILLOS A, Pinyol M, Delgado J, Aymerich M, et al
    The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Nov 8:1-9. doi: 10.1080/10428194.2017.1397660.
    PubMed     Text format     Abstract available


  140. MCCURDY SR, Levis MJ
    Emerging molecular predictive and prognostic factors in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Nov 2:1-19. doi: 10.1080/10428194.2017.1393669.
    PubMed     Text format     Abstract available


    October 2017
  141. SATO R, Jacob J, Gaballa S
    Rapid flare of immune thrombocytopenia after stopping ibrutinib in a patient with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Oct 30:1-4. doi: 10.1080/10428194.2017.1387907.
    PubMed     Text format    


  142. STEINBRECHER D, Jebaraj BMC, Schneider C, Edelmann J, et al
    Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome.
    Leuk Lymphoma. 2017 Oct 24:1. doi: 10.1080/10428194.2017.1390236.
    PubMed     Text format     Abstract available


  143. YU J, Antic Z, van Reijmersdal SV, Hoischen A, et al
    Accurate detection of low-level mosaic mutations in pediatric acute lymphoblastic leukemia using single molecule tagging and deep-sequencing.
    Leuk Lymphoma. 2017 Oct 23:1-10. doi: 10.1080/10428194.2017.1390232.
    PubMed     Text format     Abstract available


  144. SALZER W, Bostrom B, Messinger Y, Perissinotti AJ, et al
    Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Oct 18:1-10. doi: 10.1080/10428194.2017.1386305.
    PubMed     Text format     Abstract available


  145. PENG L, Tang Y, Zhang Y, Guo S, et al
    Structural maintenance of chromosomes 4 is required for leukemia stem cell maintenance in MLL-AF9 induced acute myeloid leukemia.
    Leuk Lymphoma. 2017 Oct 18:1-8. doi: 10.1080/10428194.2017.1387906.
    PubMed     Text format     Abstract available


  146. GEYER MB, Manjunath SH, Evans AG, Park JH, et al
    Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells.
    Leuk Lymphoma. 2017 Oct 18:1-5. doi: 10.1080/10428194.2017.1390237.
    PubMed     Text format    


  147. LI WY, Wang Y, Chen SN, Qiu HY, et al
    Consolidation therapy with decitabine and intermediate-dose cytarabine followed by HLA-mismatched peripheral blood stem cells infusion for older patients with acute myeloid leukemia in first remission.
    Leuk Lymphoma. 2017 Oct 18:1-7. doi: 10.1080/10428194.2017.1390235.
    PubMed     Text format     Abstract available


  148. MITSUI-SEKINAKA K, Sekinaka Y, Ogura Y, Honda M, et al
    A pediatric case of acute megakaryocytic leukemia with double chimeric transcripts of CBFA2T3-GLIS2 and DHH-RHEBL1.
    Leuk Lymphoma. 2017 Oct 18:1-3. doi: 10.1080/10428194.2017.1387901.
    PubMed     Text format    


  149. CORROCHER FA, Bueno de Paiva L, Duarte ASS, Ferro KP, et al
    Reduced expression of NR4A1 activates glycolytic pathway in acute promyelocytic leukemia cells.
    Leuk Lymphoma. 2017 Oct 17:1-4. doi: 10.1080/10428194.2017.1387900.
    PubMed     Text format    


  150. MOTOHASHI K, Fujisawa S, Doki N, Kobayashi T, et al
    Cytogenetic risk stratification may predict allogeneic hematopoietic stem cell transplantation outcomes for chronic myelomonocytic leukemia.
    Leuk Lymphoma. 2017 Oct 16:1-6. doi: 10.1080/10428194.2017.1387913.
    PubMed     Text format     Abstract available


  151. LEE LJ, Toze CL, Huang SJT, Gillan TL, et al
    Improved survival outcomes with the addition of rituximab to initial therapy for chronic lymphocytic leukemia: a comparative effectiveness analysis in the province of British Columbia, Canada.
    Leuk Lymphoma. 2017 Oct 16:1-8. doi: 10.1080/10428194.2017.1387904.
    PubMed     Text format     Abstract available


  152. ZHANG C, Amos Burke GA
    Pediatric precursor B-cell acute lymphoblastic leukemia with MYC 8q24 translocation - how to treat?
    Leuk Lymphoma. 2017 Oct 12:1-7. doi: 10.1080/10428194.2017.1387914.
    PubMed     Text format     Abstract available


  153. KATAGIRI S, Umezu T, Azuma K, Asano M, et al
    Hidden FLT3-D835Y clone in FLT3-ITD-positive acute myeloid leukemia that evolved into very late relapse with T-lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Oct 3:1-4. doi: 10.1080/10428194.2017.1382696.
    PubMed     Text format    


  154. VANGAPANDU HV, Chen H, Wierda WG, Keating MJ, et al
    Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells.
    Leuk Lymphoma. 2017 Oct 3:1-12. doi: 10.1080/10428194.2017.1376747.
    PubMed     Text format     Abstract available


    September 2017
  155. HOOGEVEEN PG, de Bie M, Noordijk R, Sonneveld E, et al
    Pitfalls in short-tandem repeat analysis as quality control for sample mix-up of pediatric acute lymphoblastic leukemia patients.
    Leuk Lymphoma. 2017 Sep 28:1-3. doi: 10.1080/10428194.2017.1382699.
    PubMed     Text format    


  156. APPLEBY N, O'Brien D, Quinn FM, Smyth L, et al
    Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-
    Leuk Lymphoma. 2017 Sep 19:1-10. doi: 10.1080/10428194.2017.1376746.
    PubMed     Text format     Abstract available


  157. ANDRITSOS LA, Grieselhuber NR, Anghelina M, Rogers KA, et al
    Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia.
    Leuk Lymphoma. 2017 Sep 18:1-4. doi: 10.1080/10428194.2017.1365853.
    PubMed     Text format    


  158. KREINITZ N, Polliack A, Tadmor T
    Chronic lymphocytic leukemia is becoming more complex: how to define complex karyotype?
    Leuk Lymphoma. 2017 Sep 18:1-2. doi: 10.1080/10428194.2017.1376748.
    PubMed     Text format    


  159. RIZZOTTO L, Lai TH, Bottoni A, Woyach JA, et al
    Role and regulation of microRNAs targeting BTK in acute myelogenous leukemia.
    Leuk Lymphoma. 2017 Sep 18:1-5. doi: 10.1080/10428194.2017.1376742.
    PubMed     Text format    


  160. VLIJM-KIEVIT A, Jorna NGE, Moll E, Pajkrt E, et al
    Acute lymphoblastic leukemia during the third trimester of pregnancy.
    Leuk Lymphoma. 2017 Sep 15:1-3. doi: 10.1080/10428194.2017.1375104.
    PubMed     Text format    


  161. MULANOVICH V, Kontoyiannis DP
    Acute myeloid leukemia and the infectious diseases consultant.
    Leuk Lymphoma. 2017 Sep 15:1-8. doi: 10.1080/10428194.2017.1365861.
    PubMed     Text format     Abstract available


  162. MESCHER C, Gilbertson D, Randall NM, Tarchand G, et al
    The impact of Agent Orange exposure on prognosis and management in patients with chronic lymphocytic leukemia: a National Veteran Affairs Tumor Registry Study.
    Leuk Lymphoma. 2017 Sep 14:1-8. doi: 10.1080/10428194.2017.1375109.
    PubMed     Text format     Abstract available


  163. VAUGHN JL, Kline D, Denlinger NM, Andritsos LA, et al
    Predictive performance of early warning scores in acute leukemia patients receiving induction chemotherapy.
    Leuk Lymphoma. 2017 Sep 13:1-3. doi: 10.1080/10428194.2017.1376744.
    PubMed     Text format    


  164. TAVARES M, Lemiale V, Mokart D, Pene F, et al
    Determinants of 1-year survival in critically ill acute leukemia patients: a GRRR-OH study.
    Leuk Lymphoma. 2017 Sep 13:1-9. doi: 10.1080/10428194.2017.1375106.
    PubMed     Text format     Abstract available


  165. PULA A, Stawiski K, Braun M, Iskierka-Jazdzewska E, et al
    Efficacy and safety of B-cell receptor signaling pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia: a systematic review and meta-analysis of randomized clinical trials.
    Leuk Lymphoma. 2017 Sep 11:1-11. doi: 10.1080/10428194.2017.1375101.
    PubMed     Text format     Abstract available


  166. PALLAVAJJALA A, Kim D, Li T, Ghiaur G, et al
    Genomic characterization of chromosome translocations in patients with T/myeloid mixed-phenotype acute leukemia.
    Leuk Lymphoma. 2017 Sep 7:1-8. doi: 10.1080/10428194.2017.1372577.
    PubMed     Text format     Abstract available


  167. SHUKLA A, Shukla V, Joshi SS
    Regulation of MAPK signaling and implications in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Sep 7:1-9. doi: 10.1080/10428194.2017.1370548.
    PubMed     Text format     Abstract available


  168. RODRIGUEZ CM, Stanganelli C, Bussi C, Arroyo D, et al
    Intracytoplasmic filamentous inclusions and IGHV rearrangements in a patient with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Sep 3:1-5. doi: 10.1080/10428194.2017.1370549.
    PubMed     Text format    


  169. GURBUXANI S
    The web of microRNA in B lymphoblastic leukemia.
    Leuk Lymphoma. 2017;58:2024-2025.
    PubMed     Text format    


    August 2017
  170. HUANG A, Huang C, Tang G, Cheng H, et al
    Impact of clinical utility of MRD assessment with different techniques on survival in acute B lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Aug 31:1-11. doi: 10.1080/10428194.2017.1369072.
    PubMed     Text format     Abstract available


  171. BURGSTALLER S, Stauder R, Kuehr T, Lang A, et al
    A phase I study of lenalidomide in patients with chronic myelomonocytic leukemia (CMML) - AGMT_CMML-1.
    Leuk Lymphoma. 2017 Aug 30:1-6. doi: 10.1080/10428194.2017.1369070.
    PubMed     Text format     Abstract available


  172. CAO H, Xie J, Guo L, Han K, et al
    All-trans retinoic acid induces autophagic degradation of ubiquitin-like modifier activating enzyme 3 in acute promyelocytic leukemia cells.
    Leuk Lymphoma. 2017 Aug 29:1-9. doi: 10.1080/10428194.2017.1365850.
    PubMed     Text format     Abstract available


  173. BODDU P, Kantarjian H, Garcia-Manero G, Ravandi F, et al
    Time to response and survival in hypomethylating agent-treated acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 25:1-4. doi: 10.1080/10428194.2017.1365857.
    PubMed     Text format    


  174. FALANTES J, Pleyer L, Thepot S, Almeida AM, et al
    Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).
    Leuk Lymphoma. 2017 Aug 24:1-8. doi: 10.1080/10428194.2017.1365854.
    PubMed     Text format     Abstract available


  175. IACCARINO L, Ottone T, Hasan SK, Divona M, et al
    Comparative genomic analysis of PML and RARA breakpoints in paired diagnosis/relapse samples of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
    Leuk Lymphoma. 2017 Aug 24:1-3. doi: 10.1080/10428194.2017.1369067.
    PubMed     Text format    


  176. SI T, Lu Y, Li F, Jiang L, et al
    High expression of INHBA is an adverse prognostic factor for de novo acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 24:1-7. doi: 10.1080/10428194.2017.1324157.
    PubMed     Text format     Abstract available



  177. Wendtner C-M, and Gregor M. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia. Leuk Lymphoma. 2017. http://dx.doi.org/10.1080/10428194.2017.1330474.
    Leuk Lymphoma. 2017 Aug 10:1. doi: 10.1080/10428194.2017.1363546.
    PubMed     Text format    


  178. CRUZ NM, Sugita M, Ewing-Crystal N, Lam L, et al
    Selection and characterization of antibody clones are critical for accurate flow cytometry-based monitoring of CD123 in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 10:1-5. doi: 10.1080/10428194.2017.1361023.
    PubMed     Text format    


  179. JALBUT MM, Brunner AM, Amrein PC, Ballen KK, et al
    Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 9:1-4. doi: 10.1080/10428194.2017.1361028.
    PubMed     Text format    


  180. CHEN X, Dou H, Wang X, Huang Y, et al
    KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 9:1-8. doi: 10.1080/10428194.2017.1361025.
    PubMed     Text format     Abstract available


  181. CAYSSIALS E, Tartarin F, Guilhot J, Sorel N, et al
    Sustained molecular response in chronic myeloid leukemia deep responders treated with low dose tyrosine kinase inhibitors.
    Leuk Lymphoma. 2017 Aug 9:1-4. doi: 10.1080/10428194.2017.1357178.
    PubMed     Text format    


  182. DHERE V, Edelman S, Waller EK, Langston A, et al
    Myeloablative busulfan/cytoxan conditioning versus reduced-intensity fludarabine/melphalan conditioning for allogeneic hematopoietic stem cell transplant in patients with acute myelogenous leukemia.
    Leuk Lymphoma. 2017 Aug 7:1-7. doi: 10.1080/10428194.2017.1361027.
    PubMed     Text format     Abstract available


  183. KIVIOJA JL, Lopez Marti JM, Kumar A, Kontro M, et al
    Chimeric NUP98-NSD1 transcripts from the cryptic t(5;11)(q35.2;p15.4) in adult de novo acute myeloid leukemia.
    Leuk Lymphoma. 2017 Aug 4:1-8. doi: 10.1080/10428194.2017.1357174.
    PubMed     Text format     Abstract available


  184. DIRSE V, Norvilas R, Gineikiene E, Matuzeviciene R, et al
    ETV6 and NOTCH1 germline variants in adult acute leukemia.
    Leuk Lymphoma. 2017 Aug 4:1-3. doi: 10.1080/10428194.2017.1359742.
    PubMed     Text format    


  185. SESE L, Rivaud E, Bron C, Leblond V, et al
    Unexpected Pneumocystis jirovecii pneumonia in patients with untreated chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Aug 3:1-4. doi: 10.1080/10428194.2017.1357170.
    PubMed     Text format    


  186. MULCAHY A, Mulligan SP, Shumack SP
    Recommendations for skin cancer monitoring for patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Aug 3:1-5. doi: 10.1080/10428194.2017.1349903.
    PubMed     Text format    


  187. WANG A, Cai X, Qiang P, Duan Q, et al
    Successful treatment of a patient with acute promyelocytic leukemia with a STAT5B/RARA fusion gene using decitabine.
    Leuk Lymphoma. 2017 Aug 1:1-3. doi: 10.1080/10428194.2017.1357176.
    PubMed     Text format    


    July 2017
  188. YANADA M, Mori J, Aoki J, Harada K, et al
    Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients.
    Leuk Lymphoma. 2017 Jul 28:1-9. doi: 10.1080/10428194.2017.1357173.
    PubMed     Text format     Abstract available


  189. GEYER MB, Tallman MS
    Digging deeper in relapsed acute lymphoblastic leukemia: impact of MRD status on outcome in second remission.
    Leuk Lymphoma. 2017 Jul 28:1-3. doi: 10.1080/10428194.2017.1355971.
    PubMed     Text format    


  190. KONG J, Zhao XS, Qin YZ, Zhu HH, et al
    The initial level of MLL-partial tandem duplication affects the clinical outcomes in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jul 26:1-6. doi: 10.1080/10428194.2017.1352091.
    PubMed     Text format     Abstract available


  191. ALDOSS I, Stein AS
    Advances in adult acute lymphoblastic leukemia therapy.
    Leuk Lymphoma. 2017 Jul 26:1-18. doi: 10.1080/10428194.2017.1354372.
    PubMed     Text format     Abstract available


  192. STRICKLER N, Balabanov S, Casauro K, Schanz U, et al
    Acute central nervous system complications and ammonium levels in adult patients with acute lymphoblastic leukemia receiving l-asparaginase.
    Leuk Lymphoma. 2017 Jul 21:1-8. doi: 10.1080/10428194.2017.1352090.
    PubMed     Text format     Abstract available


  193. GONZALEZ-GASCON Y MARIN I, Hernandez-Sanchez M, Rodriguez-Vicente AE, Puiggros A, et al
    Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Jul 21:1-10. doi: 10.1080/10428194.2017.1349901.
    PubMed     Text format     Abstract available


  194. ENGLAND JT, Leitch HA
    Chronic lymphocytic leukemia in a patient with well-controlled HIV infection: successful treatment with ibrutinib.
    Leuk Lymphoma. 2017 Jul 21:1-3. doi: 10.1080/10428194.2017.1349904.
    PubMed     Text format    


  195. SHLIAKHTSITSAVA K, Romero SAD, Dewald SR, Su HI, et al
    Pregnancy and child health outcomes in pediatric and young adult leukemia and lymphoma survivors: a systematic review.
    Leuk Lymphoma. 2017 Jul 21:1-17. doi: 10.1080/10428194.2017.1352097.
    PubMed     Text format     Abstract available


  196. ALLAN JN, Roboz GJ, Askin G, Ritchie E, et al
    CD25 expression and outcomes in older patients with acute myelogenous leukemia treated with plerixafor and decitabine.
    Leuk Lymphoma. 2017 Jul 18:1-8. doi: 10.1080/10428194.2017.1352089.
    PubMed     Text format     Abstract available


  197. SHORT NJ, Kantarjian H, Ravandi F, Huang X, et al
    A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jul 18:1-8. doi: 10.1080/10428194.2017.1349907.
    PubMed     Text format     Abstract available


  198. RAUSCH CR, Marini BL, Benitez LL, Elias A, et al
    PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia dagger.
    Leuk Lymphoma. 2017 Jul 18:1-8. doi: 10.1080/10428194.2017.1349902.
    PubMed     Text format     Abstract available


  199. AMMANN EM, Shanafelt TD, Wright KB, McDowell BD, et al
    Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length.
    Leuk Lymphoma. 2017 Jul 18:1-7. doi: 10.1080/10428194.2017.1349905.
    PubMed     Text format     Abstract available


  200. HOROWITZ NA, Henig I, Henig O, Benyamini N, et al
    Acute myeloid leukemia during pregnancy: a systematic review and meta-analysis.
    Leuk Lymphoma. 2017 Jul 13:1-7. doi: 10.1080/10428194.2017.1347651.
    PubMed     Text format     Abstract available


  201. CHELYSHEVA E, Turkina A, Polushkina E, Shmakov R, et al
    Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment.
    Leuk Lymphoma. 2017 Jul 13:1-6. doi: 10.1080/10428194.2017.1347929.
    PubMed     Text format     Abstract available


  202. WILLIAMS AM, Baran AM, Meacham PJ, Feldman MM, et al
    Analysis of the risk of infection in patients with chronic lymphocytic leukemia in the era of novel therapies.
    Leuk Lymphoma. 2017 Jul 11:1-8. doi: 10.1080/10428194.2017.1347931.
    PubMed     Text format     Abstract available


  203. KREMER B, Tsai DE, Debonera F, Cohen PL, et al
    Spontaneous remission of acute myeloid leukemia after discontinuation of lenalidomide.
    Leuk Lymphoma. 2017 Jul 11:1-3. doi: 10.1080/10428194.2017.1347652.
    PubMed     Text format    


  204. GARRISI VM, Sgherza N, Breccia M, Iacobazzi A, et al
    Association between proteomic profile and molecular response in chronic myeloid leukemia patients.
    Leuk Lymphoma. 2017 Jul 11:1-3. doi: 10.1080/10428194.2017.1344841.
    PubMed     Text format    


  205. DAMLAJ M, Al Balwi M, Al Mugairi AM
    Ibrutinib therapy is effective in B-cell prolymphocytic leukemia exhibiting MYC aberrations.
    Leuk Lymphoma. 2017 Jul 11:1-4. doi: 10.1080/10428194.2017.1347653.
    PubMed     Text format    


  206. SAYGIN C, Papadantonakis N, Cassaday RD, Liedtke M, et al
    Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response.
    Leuk Lymphoma. 2017 Jul 11:1-9. doi: 10.1080/10428194.2017.1344842.
    PubMed     Text format     Abstract available


  207. CALVELLO C, Rocca B, Klersy C, Zappatore R, et al
    Alternative splicing of hTERT: a further mechanism for the control of active hTERT in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jul 6:1-8. doi: 10.1080/10428194.2017.1346252.
    PubMed     Text format     Abstract available


  208. SALMOIRAGHI S, Rambaldi A, Spinelli O
    TP53 in adult acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Jul 6:1-12. doi: 10.1080/10428194.2017.1344839.
    PubMed     Text format     Abstract available


  209. XU W, Li X, Quan L, Yao J, et al
    Arsenic trioxide decreases the amount and inhibits the function of regulatory T cells, which may contribute to its efficacy in the treatment of acute promyelocytic leukemia.
    Leuk Lymphoma. 2017 Jul 6:1-10. doi: 10.1080/10428194.2017.1346253.
    PubMed     Text format     Abstract available


  210. HAMPRAS SS, Locke FL, Chavez JC, Patel NS, et al
    Prevalence of cutaneous viral infections in incident cutaneous squamous cell carcinoma detected among chronic lymphocytic leukemia and hematopoietic stem cell transplant patients.
    Leuk Lymphoma. 2017 Jul 6:1-7. doi: 10.1080/10428194.2017.1342822.
    PubMed     Text format     Abstract available


  211. XU L, Zhang M, Li H, Guan W, et al
    SH3BGRL as a novel prognostic biomarker is down-regulated in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jul 6:1-13. doi: 10.1080/10428194.2017.1344843.
    PubMed     Text format     Abstract available


    June 2017
  212. KATKISH LA, Rangaraju S, Rector TS, Gravely AA, et al
    Incidence of unprovoked venous thromboembolic events in patients with chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Jun 27:1-3. doi: 10.1080/10428194.2017.1341979.
    PubMed     Text format    


  213. SANDOVAL-SUS JD, Chavez JC, Dalia S, Naqvi SMH, et al
    Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Jun 22:1-10. doi: 10.1080/10428194.2017.1323271.
    PubMed     Text format     Abstract available


  214. BORUTINSKAITE V, Virksaite A, Gudelyte G, Navakauskiene R, et al
    Green tea polyphenol EGCG causes anti-cancerous epigenetic modulations in acute promyelocytic leukemia cells.
    Leuk Lymphoma. 2017 Jun 22:1-10. doi: 10.1080/10428194.2017.1339881.
    PubMed     Text format     Abstract available


  215. MAFFEI R, Fiorcari S, Martinelli S, Benatti S, et al
    Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.
    Leuk Lymphoma. 2017 Jun 22:1-11. doi: 10.1080/10428194.2017.1339872.
    PubMed     Text format     Abstract available


  216. SANIKOMMU SR, Clemente MJ, Chomczynski P, Afable MG 2nd, et al
    Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL).
    Leuk Lymphoma. 2017 Jun 20:1-7. doi: 10.1080/10428194.2017.1339880.
    PubMed     Text format     Abstract available


  217. VILLEMAGNE SANCHEZ LA, O'Callaghan C, Gough K, Hall K, et al
    Patient perceptions of treatment-free remission in chronic myeloid leukemia.
    Leuk Lymphoma. 2017 Jun 15:1-10. doi: 10.1080/10428194.2017.1337114.
    PubMed     Text format     Abstract available


  218. KANSAGRA A, Dahiya S, Litzow M
    Continuing challenges and current issues in acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 Jun 11:1-16. doi: 10.1080/10428194.2017.1335397.
    PubMed     Text format     Abstract available


  219. FARSHCHI ZARABI S, Chan S, Gupta V, Khalaf D, et al
    Remissions after third induction chemotherapy for primary non-responders with acute myeloid leukemia (AML) are uncommon and short-lived.
    Leuk Lymphoma. 2017 Jun 9:1-4. doi: 10.1080/10428194.2017.1323273.
    PubMed     Text format    


  220. DROIN N, Lucas N, Parinet V, Selimoglu-Buet D, et al
    Eosinophil-rich tissue infiltrates in chronic myelomonocytic leukemia patients.
    Leuk Lymphoma. 2017 Jun 8:1-5. doi: 10.1080/10428194.2017.1330468.
    PubMed     Text format     Abstract available


  221. LARSEN CM, Villarraga HR, Begna KH, Litzow MR, et al
    Cardiovascular effects of the addition of nilotinib to standard therapy for acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jun 8:1-4. doi: 10.1080/10428194.2017.1323268.
    PubMed     Text format    


  222. TIONG IS, Tan P, McManus J, Cummings N, et al
    Phase Ib study of the mTOR inhibitor everolimus with low dose cytarabine in elderly acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jun 8:1-4. doi: 10.1080/10428194.2017.1334122.
    PubMed     Text format    


  223. NASILLO V, Paolini A, Riva G, Morselli M, et al
    Effectiveness of originator (Neupogen) and biosimilar (Zarzio) filgrastim in autologous peripheral blood stem cell mobilization in adults with acute myeloid leukemia: a single-center retrospective study.
    Leuk Lymphoma. 2017 Jun 7:1-4. doi: 10.1080/10428194.2017.1321748.
    PubMed     Text format    


  224. MEGIAS-VERICAT JE, Montesinos P, Herrero MJ, Moscardo F, et al
    Influence of cytarabine metabolic pathway polymorphisms in acute myeloid leukemia induction treatment.
    Leuk Lymphoma. 2017 Jun 2:1-15. doi: 10.1080/10428194.2017.1323267.
    PubMed     Text format     Abstract available


  225. BHATT VR, Gundabolu K, Koll T, Maness LJ, et al
    Initial therapy for acute myeloid leukemia in older patients: principles of care.
    Leuk Lymphoma. 2017 Jun 2:1-13. doi: 10.1080/10428194.2017.1323275.
    PubMed     Text format     Abstract available


  226. SOLE C, Martinez D, Gine E, Gonzalez-Farre B, et al
    Expression of a truncated B lymphocyte-induced maturation protein-1 isoform is associated with an incomplete plasmacytic differentiation program in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Jun 2:1-4. doi: 10.1080/10428194.2017.1330470.
    PubMed     Text format    


  227. NGUYEN D, Haley L, Pallavajjala A, Gojo I, et al
    Identification of a novel KMT2A-SEPT14 fusion in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Jun 2:1-3. doi: 10.1080/10428194.2017.1324163.
    PubMed     Text format    


  228. WEBSTER JA, Pratz KW
    Acute myeloid leukemia in the elderly: therapeutic options and choice.
    Leuk Lymphoma. 2017 Jun 2:1-14. doi: 10.1080/10428194.2017.1330956.
    PubMed     Text format     Abstract available


  229. WENDTNER CM, Gregor M
    Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Jun 1:1-11. doi: 10.1080/10428194.2017.1330474.
    PubMed     Text format     Abstract available


  230. PIGGIN A, Bayly E, Tam CS
    Novel agents versus chemotherapy as frontline treatment of CLL.
    Leuk Lymphoma. 2017;58:1320-1324.
    PubMed     Text format     Abstract available


    May 2017
  231. GAFTER-GVILI A
    G6PD deficiency and fungal infections in patients with acute myeloid leukemia: less enzyme more fungus.
    Leuk Lymphoma. 2017 May 31:1-2. doi: 10.1080/10428194.2017.1330478.
    PubMed     Text format    


  232. MOTLLO C, Ribera JM, Morgades M, Granada I, et al
    Frequency and prognostic significance of additional cytogenetic abnormalities to the Philadelphia chromosome in young and older adults with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 May 30:1-9. doi: 10.1080/10428194.2017.1326596.
    PubMed     Text format     Abstract available


  233. LEE SE, Choi SY, Kim SH, Song HY, et al
    Baseline BCR-ABL1 transcript type of e13a2 and large spleen size are predictors of poor long-term outcomes in chronic phase chronic myeloid leukemia patients who failed to achieve an early molecular response after 3 months of imatinib therapy.
    Leuk Lymphoma. 2017 May 25:1-9. doi: 10.1080/10428194.2017.1320711.
    PubMed     Text format     Abstract available


  234. SAINI L, Brandwein J, Szkotak A, Ghosh S, et al
    Persistent cytogenetic abnormalities in patients undergoing intensive chemotherapy for acute myeloid leukemia.
    Leuk Lymphoma. 2017 May 25:1-8. doi: 10.1080/10428194.2017.1326032.
    PubMed     Text format     Abstract available


  235. XU X, Nagel S, Quentmeier H, Wang Z, et al
    KDM3B shows tumor-suppressive activity and transcriptionally regulates HOXA1 through retinoic acid response elements in acute myeloid leukemia.
    Leuk Lymphoma. 2017 May 25:1-10. doi: 10.1080/10428194.2017.1324156.
    PubMed     Text format     Abstract available


  236. HOSHINO T, Taki T, Takada S, Hatsumi N, et al
    Spontaneous remission of adult acute myeloid leukemia with t(8;16)(p11;p13)/MOZ-CBP fusion.
    Leuk Lymphoma. 2017 May 23:1-3. doi: 10.1080/10428194.2017.1320712.
    PubMed     Text format    


  237. BRECCIA M, Efficace F
    Are chronic myeloid leukemia patients ready to stop long-term treatment?
    Leuk Lymphoma. 2017 May 23:1-3. doi: 10.1080/10428194.2017.1330476.
    PubMed     Text format    


  238. LARSON RA
    Managing CNS disease in adults with acute lymphoblastic leukemia.
    Leuk Lymphoma. 2017 May 23:1-11. doi: 10.1080/10428194.2017.1326597.
    PubMed     Text format     Abstract available


  239. BUTTNER B, Knoth H, Kramer M, Oertel R, et al
    Impact of pharmacokinetics on the toxicity and efficacy of clofarabine in patients with relapsed or refractory acute myeloid leukemia.
    Leuk Lymphoma. 2017 May 16:1-10. doi: 10.1080/10428194.2017.1319051.
    PubMed     Text format     Abstract available


  240. TANOUE S, Konuma T, Takahashi S, Watanabe E, et al
    Long-term persistent donor-recipient mixed chimerism without disease recurrence after myeloablative single-unit cord blood transplantation in adult acute myeloid leukemia following myelodysplastic syndrome.
    Leuk Lymphoma. 2017 May 16:1-3. doi: 10.1080/10428194.2017.1318440.
    PubMed     Text format    


  241. CAMPREGHER PV, Halley NDS, Vieira GA, Fernandes JF, et al
    Identification of a novel fusion TBL1XR1-PDGFRB in a patient with acute myeloid leukemia harboring the DEK-NUP214 fusion and clinical response to dasatinib.
    Leuk Lymphoma. 2017 May 16:1-4. doi: 10.1080/10428194.2017.1318437.
    PubMed     Text format    


  242. OWEN C, Christofides A, Johnson N, Lawrence T, et al
    Use of minimal residual disease assessment in the treatment of chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 May 16:1-9. doi: 10.1080/10428194.2017.1318439.
    PubMed     Text format     Abstract available


  243. BUSCA A, Lessi F, Verga L, Candoni A, et al
    SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy.
    Leuk Lymphoma. 2017 May 16:1-6. doi: 10.1080/10428194.2017.1318438.
    PubMed     Text format     Abstract available


  244. OKABE S, Tauchi T, Tanaka Y, Ohyashiki K, et al
    Targeting peroxisome proliferator-activated receptors: a novel strategy for Philadelphia chromosome-positive leukemia cells.
    Leuk Lymphoma. 2017 May 15:1-3. doi: 10.1080/10428194.2017.1312373.
    PubMed     Text format    


  245. ZHAO B, Bhattacharya S, Yu Q, Fuchs SY, et al
    Expression of the IFNAR1 chain of type 1 interferon receptor in benign cells protects against progression of acute leukemia.
    Leuk Lymphoma. 2017 May 15:1-7. doi: 10.1080/10428194.2017.1319053.
    PubMed     Text format     Abstract available


  246. SHANMUGANATHAN N, Hiwase DK, Ross DM
    Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome.
    Leuk Lymphoma. 2017 May 9:1-12. doi: 10.1080/10428194.2017.1312377.
    PubMed     Text format     Abstract available


  247. AW A, Brown JR
    The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 May 9:1-11. doi: 10.1080/10428194.2017.1312387.
    PubMed     Text format     Abstract available


  248. COLOMER-LAHIGUERA S, Pisecker M, Konig M, Nebral K, et al
    MEF2C-dysregulated pediatric T-cell acute lymphoblastic leukemia is associated with CDKN1B deletions and a poor response to glucocorticoid therapy.
    Leuk Lymphoma. 2017 May 9:1-10. doi: 10.1080/10428194.2017.1312383.
    PubMed     Text format     Abstract available


    April 2017
  249. LIU H, Zhang J, Ren S, Chen M, et al
    Using low-dose homoharringtonine and cytarabine in combination with granulocyte colony-stimulating factor in a priming induction therapy for acute myeloid leukemia: a retrospective study of 29 cases in china.
    Leuk Lymphoma. 2017 Apr 13:1-4. doi: 10.1080/10428194.2017.1312378.
    PubMed     Text format    


  250. DRENNAN AC, Rui L
    HiJAKing the epigenome in leukemia and lymphoma.
    Leuk Lymphoma. 2017 Apr 12:1-8. doi: 10.1080/10428194.2017.1312370.
    PubMed     Text format     Abstract available


  251. SANNA M, Caocci G, Ledda A, Orru F, et al
    Glucose-6-phosphate dehydrogenase deficiency and risk of invasive fungal disease in patients with acute myeloid leukemia.
    Leuk Lymphoma. 2017 Apr 12:1-10. doi: 10.1080/10428194.2017.1312666.
    PubMed     Text format     Abstract available


  252. BOSCH R, Mora A, Vicente EP, Ferrer G, et al
    FcgammaRIIb expression in early stage chronic lymphocytic leukemia.
    Leuk Lymphoma. 2017 Apr 4:1-7. doi: 10.1080/10428194.2017.1307981.
    PubMed     Text format     Abstract available


  253. WASHIO K, Oka T, Abdalkader L, Muraoka M, et al
    Gene expression analysis of hypersensitivity to mosquito bite, chronic active EBV infection and NK/T-lymphoma/leukemia.
    Leuk Lymphoma. 2017 Apr 3:1-12. doi: 10.1080/10428194.2017.1304762.
    PubMed     Text format     Abstract available


  254. HARIVENKATESH N, Kumar L, Bakhshi S, Sharma A, et al
    Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy?
    Leuk Lymphoma. 2017 Apr 3:1-9. doi: 10.1080/10428194.2017.1287359.
    PubMed     Text format     Abstract available


  255. ROBESOVA B, Jeziskova I, Krejci M, Mayer J, et al
    Genesis of new allele at locus D2S1360 in leukemia patient.
    Leuk Lymphoma. 2017 Apr 3:1-4. doi: 10.1080/10428194.2017.1307363.
    PubMed     Text format    


  256. BEAUPIN LK, Bostrom B, Barth MJ, Franklin I, et al
    Pegaspargase hypersensitivity reactions: intravenous infusion versus intramuscular injection - a review.
    Leuk Lymphoma. 2017;58:766-772.
    PubMed     Text format     Abstract available


    March 2017
  257. RAFELSON WM, Reagan JL, Fast LD, Lim SH, et al
    Immunotherapy of elderly acute myeloid leukemia: light at the end of a long tunnel?
    Leuk Lymphoma. 2017 Mar 28:1-9. doi: 10.1080/10428194.2017.1306646.
    PubMed     Text format     Abstract available


  258. CHEN X, Othus M, Wood BL, Walter RB, et al
    Flow cytometric demonstration of decrease in bone marrow leukemic blasts after 'Day 14' without further therapy in acute myeloid leukemia.
    Leuk Lymphoma. 2017 Mar 28:1-3. doi: 10.1080/10428194.2017.1307359.
    PubMed     Text format    


  259. HEISEL RW, Sutton RR, Mascara GP, Winger DG, et al
    Vancomycin-resistant enterococci in acute myeloid leukemia and myelodysplastic syndrome patients undergoing induction chemotherapy with idarubicin and cytarabine.
    Leuk Lymphoma. 2017 Mar 28:1-8. doi: 10.1080/10428194.2017.1306645.
    PubMed     Text format     Abstract available


    January 2016
  260. GRYGOROWICZ MA, Biernacka M, Bujko M, Nowak E, et al
    Human regulatory T cells suppress proliferation of B lymphoma cells.
    Leuk Lymphoma. 2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: